Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.64 |
| ▸ | NAAA | Q02083 | 1/20 | 0.60 |
| ▸ | EPHX1 | P07099 | 8/20 | 0.59 |
| ▸ | FAAH | O00519 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.51 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22340820 | 1.00 | CASP2 (0.64) | CASP2NAAAEPHX1FAAHMEN1 | |
| SCHEMBL21613628 | 1.00 | CASP2 (0.64) | CASP2NAAAEPHX1FAAHMEN1 | |
| SCHEMBL25950981 | 1.00 | CASP2 (0.64) | CASP2NAAAEPHX1FAAHMEN1 | |
| SCHEMBL19606563 | 0.98 | CASP2 (0.61) | CASP2NAAAEPHX1FAAHMEN1 | |
| SCHEMBL8209484 | 0.91 | CASP2 (0.52) | CASP2NAAAEPHX1FAAHMEN1 | |
| SCHEMBL25449079 | 0.91 | EPHX2 (0.65) | EPHX2LPAR1 | |
| SCHEMBL11832089 | 0.91 | EPHX2 (0.65) | EPHX2LPAR1 | |
| SCHEMBL25477974 | 0.89 | S1PR2 (0.53) | CASP2NAAAEPHX1FAAH | |
| SCHEMBL25091844 | 0.86 | CASP2 (0.68) | CASP2NAAAFAAHMEN1KMT2A | |
| SCHEMBL13864762 | 0.86 | CASP2 (0.49) | CASP2NAAAEPHX1FAAHEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8945526-B2 | Amphiphilic substance, and drug delivery system and molecular imaging system using the same | SHIMADZU CORPORATION (JP) | 2015-02-03 | — | — | US | disclosed |
| US-20080019908-A1 | Novel amphiphilic substance, and drug delivery system and molecular imaging system using the same | SHIMADZU CORPORATION (JP) | 2008-01-24 | — | — | US | disclosed |
| EP-0144290-A2 | Substituted ethylenediamine derivatives | CIBA-GEIGY AG (CH) | 1985-06-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080019908-A1 | Novel amphiphilic substance, and drug delivery system and molecular imaging system using the same | SLC43A1, FABP1, SPNS2 | CASP2 1606/4885NAAA 588/4885EPHX1 2650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.